Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAPR tropoelastin versus Juvederm Ultra Plus for nasolabial folds
ACTRN12612000320853Phase 2Completed
- Sponsor
- Elastagen
- Start
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous aging comparing ELAPR002b split-face versus Juvederm Ultra Plus with ELAPR002d split-face versus Juvederm Ultra Plus (2 arms). Primary endpoints: Change from baseline in nasolabial fold severity by investigator and blinded third-party rater using Wrinkle Severity Rating Scale and Change from baseline in nasolabial fold severity using Wrinkle Severity Rating Scale. Started Jan 2012; status: completed.
02
Drugs
ELAPR002bELAPR002dJuvéderm
03
Conditions
cutaneous aging
Beyond the preview
Go deeper on ACTRN12612000320853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000320853.